NEO6860, a TRPV1 Antagonist, First in Human Study

This is an interventional treatment trial for Osteoarthritis, Knee Read More

Inclusion Criteria:

Males and females Any ethnic origin Between 18 and 55 years of age Body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive Body weight between 50 kg and 100 kg inclusive Subjects must be in good health, as determined by Medical history, Physical examination, Vital sign assessment, 12-lead electrocardiogram (ECG), Clinical laboratory evaluations (congenital non-haemolytic hyperbilirubinaemia is acceptable) Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions

Exclusion Criteria:

Male subjects who are not willing, or whose partners are not willing, to use appropriate contraception (such as a condom with spermicidal foam/gel/film/cream/suppository), or to refrain from donating sperm from the time of the first dose until 3 months after the final dosing occasion.

Subjects who have donated blood in the 3 months prior to screening, plasma in the 7 days prior to screening or platelets in the 6 weeks prior to screening Subjects who consume more than 28 units of alcohol per week if male or consume more than 21 units of alcohol per week if female

Subjects who have used any medication within 7 days of the first dose administration, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety:

Subjects who have a clinically significant pulse rate, blood pressure or temperature that, in the opinion of the investigator, increases the risk of participating in the study, in accordance with the CRU reference ranges at screening and prior to first dose Subjects with a positive urine drug screen (confirmed by repeat) at screening or first admission, or a positive alcohol breath test result (confirmed by repeat) at screening or first admission Subjects who have an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risk of participating in the study, in accordance with the CRU reference ranges at screening Subjects with, or with a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological or other major disorders as determined by the Investigator ALT or AST >1.5 times ULN at screening and/or prior to first dose, confirmed by repeat testing Subjects considered non-acceptable responders to the intradermal capsaicin test at screening, defined as maximum VAS score of <3 or 10 Subjects who, in the opinion of the Investigator, should not participate in the study